This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
CRD summary
The study investigated the clinical and monetary benefit of information technology-enabled diabetes management (ITDM) for patients aged over 25 years. The authors concluded that ITDM has the potential to improve process of care, prevent the development of diabetes complications, and generate cost-savings. Provider-based registry was the most beneficial technology. The study methodology appears appropriate and was generally reported clearly, although more transparent reporting of the costing would have been beneficial. The conclusions appear to reflect the available evidence.
Type of economic evaluation
Cost-benefit analysis
Study objective
The study investigated clinical and monetary benefit of information technology-enabled diabetes management (ITDM) for patients aged over 25 years.
Interventions
The six information technologies investigated in the study were as follows:
payer-sponsored system that connected to electronic claim system to track and monitor diabetes-specific information;
provider-based diabetes registries that tracked patients and their diabetes-specific information;
provider-based clinical decision support systems that produced warning of potential errors and presented treatment options through comparing patient information with electronic medical recorders; remote monitoring technologies that facilitated clinical information transfer from the patient's home to the provider's office; self-management technologies that improve the patient's ability in disease management between provider visits through the use of education resources and a data-gathering system; and integrated management systems that were assumed to support a full range of diabetes management activities.
Location/setting
USA/primary care.
Methods

Analytical approach:
A computer simulation model was created to project the clinical outcomes and monetary benefit of the disease management technologies over 10 years. This model assumed that the diabetes management technologies were developed at an annual rate of 20% until full national implementation was attained in the 5th year. The burden of disease was estimated through use of a Markov model based on diabetes disease states (e.g. diabetic retinopathy, treated retinopathy and blindness). The cycle length used in the Markov model was not stated. The authors did not state the perspective of the study.
